GLP-1s and Sleep Apnea: What Zepbound's OSA Approval Actually Means

On December 20, 2024, the FDA approved Zepbound (tirzepatide) as the first drug treatment for obstructive sleep apnea (OSA) — not as an off-label bonus effect, but as its own labeled indication, backed by two randomized, placebo-controlled trials². If you have OSA and obesity, that changes the calculus on which GLP-1 is worth asking your provider about. Here is what the trial actually found and what it does not mean.

What the FDA approved, exactly

Zepbound is indicated, in combination with a reduced-calorie diet and increased physical activity, to treat moderate-to-severe OSA in adults with obesity². The approval rests on SURMOUNT-OSA, a pair of Phase 3 randomized, double-blind, placebo-controlled trials totaling 469 adults with moderate-to-severe OSA and obesity¹. One trial enrolled people unable or unwilling to use CPAP (positive airway pressure) therapy; the other enrolled people already using CPAP, testing tirzepatide as an add-on. Both showed a real effect: participants on tirzepatide had significantly greater reductions in the apnea-hypopnea index (AHI) — the number of breathing interruptions per hour of sleep — than those on placebo¹. A 2026 secondary analysis of the same trial also found improvements in OSA-related cardiometabolic risk markers, not just the AHI number itself⁵.

Why weight loss treats sleep apnea at all

OSA happens when soft tissue in the upper airway collapses during sleep, and excess weight — particularly fat around the neck and upper airway — is one of the strongest modifiable risk factors². Zepbound's mechanism is appetite and food-intake reduction via the GLP-1 and GIP receptors, the same mechanism behind its weight-loss indication; the FDA's own review states plainly that "by reducing body weight, studies show that Zepbound also improves OSA"². It is an indirect effect — the drug is not acting on the airway directly — but the trial data show it is a real and measurable one.

Is this specific to tirzepatide, or does semaglutide help too?

The FDA approval is specific to Zepbound (tirzepatide); Wegovy (semaglutide) does not carry an OSA indication on its label. That does not mean semaglutide has zero effect on sleep apnea — weight loss from any effective method tends to improve OSA severity to some degree, and a 2025 meta-analysis pooling GLP-1 receptor agonist trials found a consistent AHI benefit across the class³. But only tirzepatide has gone through the specific trial program and FDA review required to put OSA on the label, which is the difference between "plausibly helps" and "FDA-reviewed indication with dosing and safety data specific to this condition." If OSA is a primary reason you are considering a GLP-1, that label distinction is worth asking a prospective provider about directly.

What this does not mean

This is not a replacement for a CPAP machine or a sleep study, and the FDA approval does not say otherwise — one of the two pivotal trials specifically tested tirzepatide as an add-on for people already using CPAP, not a substitute for it¹. OSA is diagnosed with a sleep study, not inferred from weight or snoring, and treatment decisions belong to a clinician who has seen your results. If you have diagnosed OSA and obesity, the honest takeaway is that tirzepatide is now a genuine, FDA-reviewed medical option to raise with your doctor or sleep specialist — one more reason formulary breadth matters when picking a provider, which is why it is one of the six factors in our Verdict Score methodology.

Choosing a provider if OSA is part of your decision

Not every telehealth provider prescribes tirzepatide, and fewer still are positioned to discuss an OSA-specific indication with you. Run any shortlist through our provider checklist, and compare tirzepatide-specific pricing and access on the tirzepatide ruling — the same board we use to judge every provider on formulary breadth and honest pricing.

This is editorial information, not medical advice. OSA is diagnosed and treated by a clinician; do not start, stop, or substitute a GLP-1 for CPAP therapy without medical guidance.